Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision neoadjuvant umbrella trial for locally advanced resectable NSCLC
ChiCTR2100053021Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of almonertinib, furmonertinib, osimertinib, ensartinib, savolitinib and 3 more in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: objective response rate. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100053021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053021.